Instrument Inactif

Communiqués Ocera Therapeutics Inc

Actions

US67552A1088

Produits pharmaceutiques

Communiqués

02/11/17	Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ocera Therapeutics, Inc. to Mallinckrodt plc is Fair to Shareholders	BU
20/10/17	Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®	GL
23/08/17	Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017	GL
01/08/17	Ocera Therapeutics Reports Second Quarter 2017 Financial Results	GL
01/06/17	Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis	GL
26/05/17	Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2	GL
10/05/17	Ocera Therapeutics : Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics	PR
09/05/17	Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update	GL
03/05/17	Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017	GL
12/04/17	Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)	GL
27/03/17	Ocera to Present at the 16th Annual Needham Healthcare Conference	GL
10/03/17	Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update	GL
08/03/17	Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy	GL
28/02/17	Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference	GL
02/02/17	Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.	BU
30/01/17	Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy	GL
05/01/17	Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis	GL
07/12/16	Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy	GL
09/11/16	Ocera to Present at the Stifel 2016 Healthcare Conference	GL
02/11/16	Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update	GL
28/10/16	Ocera Therapeutics : Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	PU
28/10/16	Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	GL
24/10/16	Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016	GL
10/10/16	Ocera to Present at the 2016 BIO Investor Forum	GL
21/09/16	Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure	GL